The 1st ASTRO/IASLC/University of Chicago, ASCO Multidisciplinary Symposium in Thoracic Oncology was recently held in Chicago, November 13-15, 2008. The conference, chaired by Drs. Everett Vokes and Stephen Hahn, was a great success. About 800 scientists participated at the meeting and much new data was presented. The virtual meeting will be available at IASLC’s website in January 2009. The Board of Directors would like everyone to pay attention to the upcoming dead-line for the IASLC Fellowship applications (see below) on January 10, 2009. We will encourage Fellows and Young Investigators to apply. IASLC has recently launched a new website. Please visit our new website; comments can be sent to firstname.lastname@example.org. The IASLC Board of Directors reminds all members that the deadline for sending abstracts to the 13th WCLC in San Francisco 2009 is March 13, 2009. We hope to see many abstracts submitted to this conference. For the 16th WCLC 2015 six proposals were received. The decision for the hosting site will be made in June 2009. Based on the success of the IASLC/ESMO joint meeting earlier this year, a joint meeting is planned in Geneva, Switzerland, April 28-May 1, 2010. Finally, the IASLC Board of Directors wishes all the members Happy Holidays and a healthy and prosperous year 2009!
Fred R. Hirsch, MD, PhD
Editor, IASLC Newsletter
IASLC Fellowship/Young Investigator Awards:
The IASLC Fellowship/Young Investigator application was announced on the website www.iaslc.org October 1st, 2008.
Deadline for application is January 10th, 2009. The announcement and application will be posted in English, Chinese and Japanese.
2008 Chicago Multidisciplinary Symposium in Thoracic Oncology - November 13-15, 2008
There will be a link on our website, www.iaslc.org, in January. 2009.
George R. Simon, MD, FACP, FCCP is joining Fox Chase’s Medical Oncology Department as Director of Thoracic Oncology, October 2008. New contact information: email@example.com
Obituary: Professor Norman Bleehen 1930 - 2008
It was with great sadness IASLC recently received the message that our long time member, Dr. Norman Bleehen died February 1st, 2008. Dr. Bleehen was a member of the IASLC Board of Directors from 1978 – 1994 and Vice-President of the organization. Norman Bleehen was a clinical and research oncologist and a founder of academic oncology in the United Kingdom, whose reputation was acknowledged both nationally and internationally. He was the first Cancer Research Campaign Professor of Clinical Oncology and Radiotherapeutics in the University of Cambridge, where his department was particularly involved with studies on the treatment of lung and brain cancer. As chairman of the MRC Cancer Therapy Committee he realized the importance of rigorous evaluation of new drugs and treatments, particularly in lung cancer. Dr. Bleehen was chairman of the British Association for Cancer Research, president of the International Society for Radiation Oncology, and consultant to the Research Co-ordination Group of the International Atomic Energy Agency for the Improvement of Cancer Therapy. He represented the UK government in the Europe Against Cancer Programme and was particularly passionate about smoking prevention campaigns. It is therefore particularly sad that, despite being a lifelong non-smoker, he developed terminal lung cancer. He was on the editorial board of a number of major journals. He published six books and over 400 papers, chapters and editorials. He is survived by his wife.
Journal of Thoracic Oncology (JTO); December 2008:
Case-Control Study Design: What, when, and why?
Jayawant N. Mandrekar, PhD; Sumithra J. Mandrekar, PhD
Should We Recommend Surgery to Patients with Limited Small
Cell Carcinoma of the Esophagus?
Aminah Jatoi, MD; Robert C. Miller, MD
Controversies in Bronchogenic Carcinoma Following Lung
Transplantation: Type of Transplant Operation and Role of
Selim M. Arcasoy, MD, FACP, FCCP
Pathway of the Month
The CXCR4/SDF-1 Chemokine Receptor Axis: A New Target
Therapeutic for Non-small Cell Lung Cancer.
Shannon Otsuka, BSc; Gwyn Bebb, BMBCh, PhD, FRCPC
IASLC Staging Committee Article
Visceral Pleural Invasion: Pathologic Criteria and Use of Elastic
Stains: Proposal for the 7th Edition of the TNM Classification for
William D. Travis, MD; Elisabeth Brambilla, MD; Ramon Rami-Porta, MD; Eric Vallières,
MD; Masahiro Tsuboi, MD; Valerie Rusch, MD; Peter Goldstraw, FRCS; on behalf of the
International Staging Committee
Epidemiology of Non-small Cell Lung Cancer in Asian
Americans: Incidence Patterns Among Six Subgroups by
Dan J. Raz, MD, MAS; Scarlett L. Gomez, PhD; Ellen T. Chang, ScD; Jae Y. Kim, MD;
Theresa H. M. Keegan, PhD; Jane Pham, MPH; Jasleen Kukreja, MD, MPH; Robert A.
Hiatt, MD; David M. Jablons, MD
Cannabis Smoking and Risk of Lung Cancer in Men: A Pooled
Analysis of Three Studies in Maghreb.
Julien Berthiller, MSc; Kurt Straif, MD, PhD; Mathieu Boniol, PhD; Nicolas Voirin, MSc;
Veronique Benhaïm-Luzon, AA; Wided Ben Ayoub, MD; Iman Dari, MD; Slimane
Laouamri, MD; Mokhtar Hamdi-Cherif, MD, PhD; Mohamed Bartal, MD, PhD; Fahrat Ben
Ayed, MD, PhD; Annie J. Sasco, MD, PhD
Bronchogenic Carcinoma after Lung Transplantation:
Characteristics and Outcomes.
Omar A. Minai, MD; Sonia Shah, MD; Peter Mazzone, MD; Marie M. Budev, MD;
Debasis Sahoo, MBBS; Sudish Murthy, MD; David Mason, MD; Gosta Pettersson, MD;
Atul C. Mehta, MBBS
Reclassification of Neuroendocrine Tumors Improves the
Separation of Carcinoids and the Prediction of Survival.
Birgit Guldhammer Skov, MD, DrMSci; Mark Krasnik, MD; Sylvie Lantuejoul, MD, PhD;
Torsten Skov, MD, PhD; Elisabeth Brambilla, MD, PhD
Combined Evaluation of Postoperative Serum Levels of
Carcinoembryonic Antigen Less than or Equal to 2.5 ng/ml and
Absence of Vascular Invasion may Predict no Recurrence of
Stage I Adenocarcinoma Lung Cancer.
Kosuke Kashiwabara, MD; Syoh Saeki, MD; Ji-ichiro Sasaki, MD; Masanobu Nomura,
MD; Hirotsugu Kohrogi, MD
Validity of International Association for the Study of Lung
Cancer Proposals for the Revision of N Descriptors in Lung
Jin Gu Lee, MD; Chang Young Lee, MD; Mi Kyung Bae, MD; In Kyu Park, MD; Dae Joon
Kim, MD; Kil Dong Kim, MD; Kyung Young Chung, MD
11C-Acetate can be Used in Place of 18F-Fluorodeoxyglucose
for Positron Emission Tomography Imaging of Non-small Cell
Lung Cancer with Higher Sensitivity for Well-Differentiated
Hiroaki Nomori, MD, PhD; Hidekatsu Shibata, MD; Kimiichi Uno, MD, PhD; Kenichi
Iyama, MD, PhD; Yumi Honda, MD, PhD; Rumi Nakashima, MD, PhD; Kazuya
Sakaguchi, PhD; Tomoyuki Goya, MD, PhD; Iwao Takanami, MD, PhD; Kiyoshi Koizumi,
MD, PhD; Takashi Suzuki, MD, PhD; Masahiro Kaji, MD, PhD; Hirotoshi Horio, MD, PhD
Use of Maximum Intensity Projections (MIPs) for Target
Outlining in 4DCT Radiotherapy Planning.
Rebecca Muirhead, MBChB, MRCP; Stuart G. McNee, PhD; Carrie Featherstone,
MBChB, MRCP, FRCR; Karen Moore, BSc; Sarah Muscat, PhD
Efficacy and Safety of Erlotinib Monotherapy for Japanese
Patients with Advanced Non-small Cell Lung Cancer: A Phase II
Kaoru Kubota, MD, PhD; Yutaka Nishiwaki, MD; Tomohide Tamura, MD; Kazuhiko
Nakagawa, MD; Kaoru Matsui, MD; Koshiro Watanabe, MD, PhD; Toyoaki Hida, MD;
Masaaki Kawahara, MD; Nobuyuki Katakami, MD; Koji Takeda, MD; Akira Yokoyama,
MD; Kazumasa Noda, MD; Masahiro Fukuoka, MD; Nagahiro Saijo, MD, PhD
Epidermal Growth Factor Receptor-Related Tumor Markers and
Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer:
An Analysis of Patients from German Centers in the TRUST
Claus-Peter Schneider, MD; David Heigener, MD; Kathrin Schott-von-Römer, MD; Sylvia
Gütz, MD; Eckart Laack, MD; Werner Digel, MD; Wolf-Rüdiger Guschall, MD; Andreas
Franke, MD; Heinrich Bodenstein, MD; Claudia Schmidtgen, PhD; Martin Reck, MD, PhD
Phase II Study of Celecoxib and Docetaxel in Non-small Cell
Lung Cancer (NSCLC) Patients with Progression after Platinum-
Bryan J. Schneider, MD; Gregory P. Kalemkerian, MD; Michael J. Kraut, MD; Antoinette
J. Wozniak, MD; Francis P. Worden, MD; Daryn W. Smith, MS; Wei Chen, PhD; Shirish
M. Gadgeel, MD
Primary Small Cell Carcinoma of the Esophagus.
Jima Lv, MD; Jun Liang, MD; Jinwan Wang, MD; Luhua Wang, MD; Jie He, MD; Zefen
Xiao, MD; Weibo Yin, MD
Image of the Month
Hemoptysis in a Patient with Melanoma and Pulmonary
J Francis Turner Jr, MD, FACP, FCCP, FCCM; Wolfram Samlowski, MD; Laura L.
State of the Art
The Prognostic and Predictive Role of Histology in Advanced
Non-small Cell Lung Cancer: A Literature Review.
Fred R. Hirsch, MD, PhD; Anna Spreafico, MD; Silvia Novello, MD, PhD; Mary Dugan
Wood, PhD; Lorinda Simms, MSc, PStat; Mauro Papotti, MD
Pulmonary Tumor Embolism: A Rare Cause of Acute Right Heart
Failure with Elevated d-Dimers.
Robert Kridel, MD; Samir Myit, MD; Jean-Claude Pache, MD; Jean-Michel Gaspoz, MD,
Paraneoplastic Limbic Encephalitis due to Thymic Carcinoid.
Melissa Davis, BA; James G. Ravenel, MD
IASLC Election 2009:
Please note that in 2009, new members of the Board of Directors will be elected for the period of 2009-2011. Among the new members of the Board of Directors is the President Elect from Europe. In 2009 there will be an election for a President-Elect from Europe and 8 new Board members. The Board of Directors has a total of 15 Directors, 5 each from North America, Europe and Asia/Rest of World. The members should be diverse in terms of specialty and gender. The following Board of Directors will remain as members of the Board from 2009-2011. The election will take place in the Spring, 2009.
Joan Schiller, medical oncology
Harvey Pass, surgery
Elisabeth Brambilla, pathology
Wilfried Eberhardt, medical oncology
Tony Mok, medical oncology
Kwun Fong, medical oncology
Masahiro Tsuboi, surgery
Thus, the IASLC membership will need to elect 3 Board members from North
America, 3 from Europe and 2 from Asia/Rest of the World.
January 28-30, 2009 7th Annual British Thoracic Oncology Group Meeting Location: Clontarf Castle - Dublin, Ireland Contact: Dawn McKinley Email: firstname.lastname@example.org Phone: 0116 250 2811 Fax: 0116 250 2810
February 18-21, 2009 9th Annual Targeted Therapies of the Treatment of Lung Cancer meeting Location: The Fairmont Miramar Hotel - Santa Monica, California For more information: email@example.com
April 1-5, 2009 4th IASLC International Meeting on Targeted Therapies in Lung Cancer Location: Saint Paul de Vence, France For more information: firstname.lastname@example.org
August 28-29, 2009 Simposio Internacional Pos Mundial Cancer de Pulmao Location: Salvador, Bahia, Brazil Contact: Victor Email: email@example.com
New IASLC member October – November 2008:
Eduardo Arnoldo Richardet
Domingo Javier Chimondeguy
Cinta Pallares Curto
Ernest Nadal Alforja
Benny (Chung-ying) Zee
Javier Puente Vazquez
Monica Guillot Morales
Nico Van Walree
Pierre R. Theodore
Felycette Gay Lapus
Sang Hoon Han
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.
WCLC Virtual Library
September 22 - 24 2016Chicago, Illinois
Multidisciplinary Hands-On Live Learning: Molecular Testing and Personalized Therapy in Lung Cancer - Chicago, ILOctober 14 2016Chicago, IL
Multidisciplinary Hands-On Live Learning: Molecular Testing and Personalized Therapy in Lung Cancer - Philadelphia, PAOctober 21 2016Philadelphia, PA